The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access

Addiction Biology

Volumn 15, Issue 3, 2010, Pages 312-323

  Orio, Laura ^a   Wee, Sunmee ^a   Newman, Amy H ^b   Pulvirenti, Luigi ^a   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

D3 receptor; Dependence; Dopamine; Methamphetamine; Partial agonist; Self administration

Indexed keywords

CJB 090; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; METHAMPHETAMINE; N [4 [(2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 PYRIDINE 2 YLBENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 2 YL)BENZAMIDE; PG 01037; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CENTRAL STIMULANT AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; N-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUT-2-ENYL)-4-PYRIDINE-2-YLBENZAMIDE; N-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTYL)-4-(PYRIDIN-2-YL)BENZAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESPONSE; DRUG SELF ADMINISTRATION; LATIN SQUARE DESIGN; MALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; REINFORCEMENT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG ABUSE; DRUG ADMINISTRATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MOTIVATION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BENZAMIDES; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; INFUSIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; MOTIVATION; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D3; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 77953220561     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2010.00211.x     Document Type: Article

References (84)

1. Achat-Mendes C, Platt DM, Newman AH, Spealman RD (2009) The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. Psychopharmacology 206 : 73 84.
2. Ahmed SH, Koob GF (1998) Transition from moderate to excessive drug intake: change in hedonic set point. Science 282 : 298 300.
3. Ahmed SH, Koob GF (2004) Changes in response to a dopamine receptor antagonist in rats with escalating cocaine intake. Psychopharmacology 172 : 450 454.
4. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, IV-TR edn
5. Aujla H, Sokoloff P, Beninger RJ (2002) A dopamine D3 receptor partial agonist blocks the expression of conditioned activity. Neuroreport 13 : 173 176.
6. Baselt RC (1982) Disposition of Toxic Drugs and Chemicals in Man, 2nd edn.
7. Beardsley PM, Sokoloff P, Balster RL, Schwartz JC (2001) The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and d-amphetamine and is not self-administered. Behav Pharmacol 12 : 1 11.
8. Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260 : 1814 1816.
9. Cho AK, Melega WP, Kuczenski R, Segal DS (2001) Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. Synapse 39 : 161 166.
10. Collins GT, Calinski DM, Newman AH, Grundt P, Woods JH (2008) Food restriction alters N′-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther 325 : 691 697.
11. Collins GT, Truccone A, Haji-Abdi F, Newman AH, Grundt P, Rice KC, Husbands SM, Greedy BM, Enguehard-Gueiffier C, Gueiffier A, Chen J, Wang S, Katz JL, Grandy DK, Sunahara RK, Woods JH (2009) Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther 329 : 210 217.
12. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314 : 310 319.
13. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M (1993) Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21 : 717 723.
14. Crean RD, Davis SA, Von Huben SN, Lay CC, Katner SN, Taffe MA (2006) Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4- methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience 142 : 515 525.
15. Cussac D, Newman-Tancredi A, Pasteau V, Millan MJ (1999) Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol 56 : 1025 1030.
16. Degenhardt L, Roxburgh A, Black E, Bruno R, Campbell G, Kinner S, Fetherston J (2008) The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev 27 : 243 252.
17. Derlet RW, Albertson TE, Rice P (1990) Antagonism of cocaine, amphetamine, and methamphetamine toxicity. Pharmacol Biochem Behav 36 : 745 749.
18. Derlet RW, Heischober B (1990) Methamphetamine. Stimulant of the 1990s? West J Med 153 : 625 628.
19. Di CP, Underwood RJ, Hagan JJ, Everitt BJ (2003) Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28 : 329 338.
20. Duarte C, Biala G, Le BC, Hamon M, Thiebot MH (2003a) Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats. Psychopharmacology 166 : 19 32.
21. Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiebot MH (2003b) Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology 28 : 1903 1915.
22. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47 : 681 698.
23. Frances H, Le FB, Diaz J, Smirnova M, Sokoloff P (2004) Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice. Neuroreport 15 : 2245 2249.
24. Gainetdinov RR, Sotnikova TD, Grekhova TV, Rayevsky KS (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 308 : 261 269.
25. Gal K, Gyertyan I (2006) Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Drug Alcohol Depend 81 : 63 70.
26. Gilbert DB, Millar J, Cooper SJ (1995) The putative dopamine D3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res 681 : 1 7.
27. Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr., Heidbreder CA, Pak AC, Peng XQ, Xi ZX (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57 : 17 28.
28. Gorelick DA, Gardner EL, Xi ZX (2004) Agents in development for the management of cocaine abuse. Drugs 64 : 1547 1573.
29. Gowing L, Ali R, White JM (2009) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. CD002025.
30. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48 : 839 848.
31. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH (2007) Heterocyclic analogues of N-(4-(4-(2,3- dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem 50 : 4135 4146.
32. Hamidovic A, Kang UJ, de Wit H (2008) Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 28 : 45 51.
33. Heidbreder C (2008) Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 7 : 410 421.
34. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr. (2005) The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49 : 77 105.
35. Hoefer ME, Voskanian SJ, Koob GF, Pulvirenti L (2006) Effects of terguride, ropinirole, and acetyl-L-carnitine on methamphetamine withdrawal in the rat. Pharmacol Biochem Behav 83 : 403 409.
36. Hoyer D, Boddeke HW (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14 : 270 275.
37. Jimenez-Ruiz C, Berlin I, Hering T (2009) Varenicline: a novel pharmacotherapy for smoking cessation. Drugs 69 : 1319 1338.
38. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006) Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology 186 : 48 53.
39. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 : 177 184.
40. Koob GF (2008) A role for brain stress systems in addiction. Neuron 59 : 11 34.
41. Koob GF, Caine B, Markou A, Pulvirenti L, Weiss F (1994) Role for the mesocortical dopamine system in the motivating effects of cocaine. NIDA Res Monogr 145 : 1 18.
42. Koob GF, Kenneth LG, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nature Rev Drug Discov 8 : 500 515.
43. Kumar R, Riddle L, Griffin SA, Grundt P, Newman AH, Luedtke RR (2009) Evaluation of the D3 Dopamine receptor selective antagonist PG01037 on L-Dopa dependent abnormal involuntary movements in rats. Neuropharmacology 56 : 956 969.
44. Le FB, Frances H, Diaz J, Schwartz JC, Sokoloff P (2002) Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 15 : 2016 2026.
45. Le FB, Goldberg SR, Sokoloff P (2005a) The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49 : 525 541.
46. Le FB, Sokoloff P, Stark H, Goldberg SR (2005b) Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30 : 720 730.
47. Le FB, Goldberg SR, Sokoloff P (2007) Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 16 : 45 57.
48. Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N- di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A 89 : 8155 8159.
49. Madden LJ, Flynn CT, Zandonatti MA, May M, Parsons LH, Katner SN, Henriksen SJ, Fox HS (2005) Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30 : 350 359.
50. Mandyam CD, Wee S, Eisch AJ, Richardson HN, Koob GF (2007) Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis. J Neurosci 27 : 11442 11450.
51. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, Nader MA (2007) Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3- dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321 : 573 582.
52. Maxwell JC, Rutkowski BA (2008) The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 27 : 229 235.
53. McCann UD, Ricaurte GA (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24 : 333 336.
54. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, Lund J, Li JH (2008) The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 27 : 220 228.
55. Melega WP, Cho AK, Harvey D, Lacan G (2007) Methamphetamine blood concentrations in human abusers: application to pharmacokinetic modeling. Synapse 61 : 216 220.
56. Melega WP, Williams AE, Schmitz DA, DiStefano EW, Cho AK (1995) Pharmacokinetic and pharmacodynamic analysis of the actions of d-amphetamine and d-methamphetamine on the dopamine terminal. J Pharmacol Exp Ther 274 : 90 96.
57. Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Curcuruto O, Damiani F, Fabio RD, Donati D, Gentile G, Gribble A, Hamprecht D, Tedesco G, Terreni S, Tarsi L, Lightfoot A, Stemp G, Macdonald G, Smith A, Pecoraro M, Petrone M, Perini O, Piner J, Rossi T, Worby A, Pilla M, Valerio E, Griffante C, Mugnaini M, Wood M, Scott C, Andreoli M, Lacroix L, Schwarz A, Gozzi A, Bifone A, Ashby CR Jr., Hagan JJ, Heidbreder C (2007) 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists. J Med Chem 50 : 5076 5089.
58. Mordenti J, Chappell W (1989) The use of interspecies scaling in toxicokinetics. In : Yacobi A, Kelly J, Batra V, eds. Toxicokinetics and New Drug Development, pp. 42 96.
59. National Institute on Drug Abuse (2005) Medications Development Research for Treatment of Amphetamine and Methamphetamine Addiction. Report to Congree. National Institutes of Health, Department of Health and Human Services (http://www.nida.nih.gov/pdf/methmeds.pdf)
60. Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR (2003) N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists. Bioorg Med Chem Lett 13 : 2179 2183.
61. Newman AH, Grundt P, Cyriac G, Deschamps JR, Taylor M, Kumar R, Ho D, Luedtke RR (2009) N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl) butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists. J Med Chem 52 : 2559 2570.
62. Newman-Tancredi A, Cussac D, Audinot V, Pasteau V, Gavaudan S, Millan MJ (1999) G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5′-O-(3-[35S]thio)- triphosphate binding and antibody study. Mol Pharmacol 55 : 564 574.
63. Orio L, Edwards S, George O, Parsons LH, Koob GF (2009) A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions. J Neurosci 29 : 4846 4857.
64. Pak AC, Ashby CR Jr., Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL (2006) The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 9 : 585 602.
65. Paterson NE, Markou A (2003) Increased motivation for self-administered cocaine after escalated cocaine intake. Neuroreport 14 : 2229 2232.
66. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400 : 371 375.
67. Pulvirenti L, Balducci C, Piercy M, Koob GF (1998) Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 286 : 1231 1238.
68. Pulvirenti L, Koob GF (1994) Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol Sci 15 : 374 379.
69. Pulvirenti L, Koob GF (2002) Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci 23 : 151 153.
70. Richardson NR, Roberts DC (1996) Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66 : 1 11.
71. Schindler CW, Bross JG, Thorndike EB (2002) Gender differences in the behavioral effects of methamphetamine. Eur J Pharmacol 442 : 231 235.
72. Segal DM, Moraes CT, Mash DC (1997) Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 45 : 335 339.
73. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 : 146 151.
74. Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR Jr., Heidbreder C, Gaal J, Gardner EL (2008) The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 196 : 533 542.
75. Staley JK, Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16 : 6100 6106.
76. Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F (2009) Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 56 (Suppl 1 3 8.
77. Vorel SR, Ashby CR Jr., Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, Gardner EL (2002) Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 22 : 9595 9603.
78. Voronin K, Randall P, Myrick H, Anton R (2008) Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm - possible influence of self-control. Alcohol Clin Exp Res 32 : 1954 1961.
79. Wee S, Wang Z, Woolverton WL, Pulvirenti L, Koob GF (2007) Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32 : 2238 2247.
80. Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 : 969 973.
81. Withers NW, Pulvirenti L, Koob GF, Gillin JC (1995) Cocaine abuse and dependence. J Clin Psychopharmacol 15 : 63 78.
82. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 52 : S10 S13.
83. Xi ZX, Gilbert J, Campos AC, Kline N, Ashby CR Jr., Hagan JJ, Heidbreder CA, Gardner EL (2004) Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 176 : 57 65.
84. Xi ZX, Gilbert JG, Pak AC, Ashby CR Jr., Heidbreder CA, Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21 : 3427 3438.